Epigenetic Regulation of m6A Modifications in Human Cancer
Wei Zhao, Xiaoqian Qi, Lina Liu and 3 more
Molecular Therapy: Nucleic Acids · 2020
doi:10.1016/j.omtn.2019.11.022 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
N6-methyladenosine (m6A) is the most prevalent internal RNA modification, especially within eukaryotic messenger RNAs (mRNAs). m6A modifications of RNA regulate splicing, translocation, stability, and translation into proteins. m6A modifications are catalyzed by RNA methyltransferases, such as METTL3, METTL14, and WTAP (writers); the modifications are removed by the demethylases fat mass and obesity-associated protein (FTO) and ALKBH5 (ALKB homolog 5) (erasers); and the modifications are recognized by m6A-binding proteins, such as YTHDF domain-containing proteins and IGF2BPs (readers). Abnormal changes in the m6A levels of these genes are closely related to tumor occurrence and development. In this paper, we review the role of m6A in human cancer and summarize its prospective applications in cancer. Keywords: N6-methyladenosine, m6A, RNA methylation, epigenetic, cancer
Abstract licence: CC BY-NC-ND
References79
- 24.
- 38.
38 more references, whose wording the paper’s licence keeps private.
All 79 referencesCited by papers we hold5
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.